| 杨平 薛沁 闫飞 师菲 郑万祥 王福利 秦卫军 武国军 田春娟 袁建林.肾透明细胞癌MAPK9 的表达与索拉非尼疗效的关系[J].现代生物医学进展英文版,2015,15(22):4298-4302. |
| 肾透明细胞癌MAPK9 的表达与索拉非尼疗效的关系 |
| Relationship between MAPK9 Expression in Renal Clear Cell Carcinoma andthe Efficacy of Sorafenib Targeted Therapy |
| |
| DOI： |
| 中文关键词: 肾透明细胞癌 索拉菲尼 促分裂原活化蛋白激酶9 疗效 |
| 英文关键词: Renal clear cell carcinoma Sorafenib Mitogen activated protein kinase 9 Efficacy |
| 基金项目:陕西省科技统筹（2012KTCL03-03） |
|
| Hits: 705 |
| Download times: 0 |
| 中文摘要: |
| 目的：探讨肾透明细胞癌组织中MAPK9 表达及其与肾透明细胞癌主要临床病理特征之间的关系，分析MAPK9 对索拉非
尼靶向治疗疗效的关系。方法：回顾分析2006年5 月-2013 年10 月经病理确诊的32 例肾透明细胞癌转移患者的MAPK9的表
达情况。所有患者术后均服用索拉菲尼并随访；同时选取10 例距肿瘤3 cm癌旁正常肾组织作为对照。对比分析肾透明细胞癌患
者与对照组MAPK9 的阳性表达率，分析MAPK9 阳性表达与疗效的相关性，并分析MAPK9 阳性表达与生存率之间的关系。结
果：肾透明细胞癌组MAPK9 阳性表达21 例（65.6 %），较正常对照组2 例（20.0 %）有显著性差异（P＜ 0.01）。TNMⅠ～Ⅱ期
MAPK9 阳性表达12 例（85.7 %），较TNMⅢ～Ⅳ期10 例（55.6 %）有显著性差异（P＜ 0.05）；核分级1～ 2 级MAPK9 阳性表达18
例（81.8 %），较3～4级4例（40.0 %）有显著性差异（P＜ 0.05）。MAPK9 阳性表达患者与阴性表达患者疗效有显著性差异（P＜
0.05）。MAPK9 阳性患者PFS 为（646± 103）d，较阴性患者PFS为（502± 89）d，有显著性差异（P＜0.05）。MAPK9 阳性患者OS为
（866± 75）d，较阴性患者OS 为（657± 62）d，有显著性差异（P＜0.01）。结论：MAPK9 在肾透明细胞癌中高表达，与肿瘤的临床
TNM分期、病理分级相关。MAPK9阳性表达患者其靶向治疗疗效越好，提示MAPK9 可能是一个预测索拉菲尼靶向治疗肾透明
细胞癌疗效的潜在因子。 |
| 英文摘要: |
| Objective:To investigate the expression of MAPK9 in renal clear cell carcinoma and analyze the influence of MAPK9
on sorafenib targeted therapy efficacy.Methods:32 patients were enrolled and treated with sorafenib after nephrectomy. The expression
of MAPK9 was tested immunohistochemically in the 32 specimens of primary renal tumors. The survival difference between
MAPK9-positive and MAPK9-negative patients was compared, and the correlation between MAPK9 status and curative effect was
compared.Results:MAPK9 was positive expression in 21 cases of renal clear cell carcinoma (65.6 %), with significant difference
compared with control group in which MAPK was positive in 2 cases (20 %) (P < 0.01).There was 12 cases of MAPK 9 positive
expression of TNM I ~ II phase (85.7 %) , higher than that of TNM III ~ IV in 10 cases (55.6 %) with significant difference (P < 0.05);
there was 18 MAPK9-positive cases in nuclear grade 1 to grade2 (81.8%), higher than 4 cases (40 %) in3 ~ 4 grade (P < 0.05).
Progression free survival（PFS）was (646± 103) d for MAPK9 positive patients and (502± 89) d for MAPK9 negative patients, and the
difference was statistically significant(P＜0.01). Overall survival（OS）time was (866± 75) d for MAPK9 positive patients and (657± 62)
d for MAPK9 negative patients, and the difference between them was statistically significant (P＜0.01).Conclusion:MAPK9 can be a
potential predictive factor for renal clear cell carcinoma treated with sorafenib, and patients with positive MAPK9 expression might have
better prognosis and obtain longer overall survival time. |
|
View Full Text
View/Add Comment Download reader |
| Close |
